Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally.
Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free. Abstract The core of Hamburg’s research is ,
Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract Abstract The core of Hamburg’s research is ,
The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber. Abstract The core of Hamburg’s research is ,
Preclinical data showed the enzyme has no measurable cytotoxic or genotoxic side effects, making it a viable candidate for human testing. 3. 2022 Milestones: The Hamburg Therapy Hub